Overview

A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)

Status:
Terminated

Trial end date:
2020-01-01

Target enrollment:

Participant gender:

Summary

This European, prospective, multicentre, double-blind randomised study will evaluate the effect of lanreotide (120 mg every 28 days until disease progression) versus placebo in patients with metastatic/locally advanced, non-resectable, duodeno-pancreatic neuroendocrine tumours.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Federation Francophone de Cancerologie Digestive

Treatments:

Angiopeptin
Lanreotide
Somatostatin